In ordering the additional discovery, U.S. District Judge Nina Gershon pointed out that McKesson—represented by Covington & Burling—had told U.S. Magistrate Judge Steven Tiscione “in the strongest ...

Nov 5 (Reuters) - Drug distributor McKesson (MCK.N), opens new tab raised its fiscal 2026 profit forecast on Wednesday, betting on strong growth in its oncology and specialty drug distribution ...

A $152.3 million judgment accepted by Baltimore City in an opioid lawsuit against pharmaceutical companies McKesson and Cencora could be overturned after McKesson filed an appeal. The appeal was filed ...

McKesson Corporation is transforming from a traditional distributor to a tech-enabled healthcare services leader, focusing on high-margin specialty and digital solutions. Recent acquisitions (PRISM ...

McKesson Corporation is rated 'Buy' due to its transformation into a higher-growth, higher-margin healthcare services platform focused on Oncology & Multispecialty and Prescription Technology ...

Sept 23 (Reuters) - McKesson (MCK.N), opens new tab on Tuesday raised its profit forecast, as the U.S. drug distributor aims to focus on high-margin businesses such as cancer medicines to boost growth ...

Deal Rationale McKesson’s strategic focus on disciplined portfolio management involves continuous evaluation of its business segments to ensure alignment with its growth priorities and optimize ...

After market hours Thursday, McKesson divulged that it earned revenue of $90.8 billion for the period, a meaty 19% improvement over the same quarter the previous year. It also managed to grow its ...

McKesson has consistently grown ahead of the broader market in recent years. The stock’s steady earnings should attract safety-minded investors in the current climate. Margins could edge higher as the ...